Beta Phase Ends, Platform Enables E-Commerce for Developers with Introduction of iCredits™
SAN DIEGO--(BUSINESS WIRE)--May. 16, 2013-- Illumina, Inc. (NASDAQ:ILMN) today announced the full commercial availability of BaseSpace, the Company's genomics cloud computing and storage platform. BaseSpace Apps is now out of beta status, and includes a full-fledged e-commerce system that allows customers to quickly and easily purchase Illumina and third-party bioinformatics applications (apps). BaseSpace e-commerce transactions are based on BaseSpace iCredits, a medium of exchange that can be purchased and spent within BaseSpace.
BaseSpace has rapidly become a valuable platform for bioinformatics app developers. During the beta period, users launched individual BaseSpace apps more than 4,000 times. Now, with BaseSpace iCredits, developers can easily add e-commerce functionality to their apps, leveraging Illumina's complete payment solution.
"The commercial availability of BaseSpace Apps is an important milestone for both Illumina customers and BaseSpace app developers. For customers, BaseSpace has transitioned into a fully-supported bioinformatics platform; for BaseSpace app developers, BaseSpace now has a comprehensive e-commerce capability that enables them to monetize their efforts," said Alex Dickinson, Illumina's Senior Vice President, Cloud Genomics. "With rapid adoption of BaseSpace by users of Illumina's high-throughput HiSeq® next-generation sequencing systems, and the continued use of the platform by users of Illumina's MiSeq® desktop sequencing systems, the scale of growth potential for BaseSpace Apps is increasing exponentially."
"BaseSpace continues to attract a large number of app developers who can rapidly make their bioinformatics tools available to thousands of Illumina customers," added Jordan Stockton, Illumina's Director of Product Marketing, Computational Biology. "BaseSpace is designed to support apps that enable genomics research in diverse markets including cancer, microbiology, and genetic disease."
Through the BaseSpace ecosystem, a diverse collection of new apps are now available for Illumina's MiSeq and HiSeq systems. For example, Elsevier Publishing, the world's leading publisher of scientific and health information, has released a BaseSpace app that enables users to submit data directly into the peer-review publication process.
"We're excited to be working with Illumina to accelerate the scientific publication process," said Bart Wacek, Executive Publisher, Elsevier Life Sciences. "Through BaseSpace, scientists can directly submit their data and manuscript to our Genomics Data journal, allowing the data review to be an integral part of the peer-review process."
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for BaseSpace Apps and related data analysis applications and programs. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
